Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors

Inclusion Criteria: * Male or female Chinese subjects \>/- 18 years * Advanced, histologically or cytologically confirmed solid tumors * Subjects malignancies must be refractory to standard treatment or have no standard therapy available, or the subject actively refused any treatment that would be regarded standard, and/or if, in the judgment of the investigator or his/her designated associate(s), experimental treatment is clinically and ethically acceptable. * Eastern Cooperative Oncology Group performance status (ECOG-PS) 0-1; * Adequate bone marrow, liver and renal function * Life expectancy of at least 3 months Exclusion Criteria: * Unstable/uncontrolled cardiac disease * History of arterial or venous thrombotic or embolic events * Malabsorption condition * Severe renal impairment; persistent proteinuria \>/= Grade 3 * Symptomatic metastatic brain or meningeal tumors * Clinically significant bleeding \>/=Grade 3 within 30 days before start of study medication.